To overcome the challenge of low MUC16 expression on ovarian cancer cells, MUC16-specific CAR-T cells were engineered to secrete a bispecific T cell engager that targets WT1, enabling the CAR-T cells to kill ovarian cancer cells via an orthogonal mechanism. Here, MUC16 is linked to ovarian carcinoma.